Payment overview · 2025
General Payments
$147.35
8 reported records · 5 companies
Healthcare provider profile · identity verified
Catherine A Marsteller, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · RICHMOND, IN · NPI 1629286141
Verified facts
What the public records show
CMS Open Payments records show Catherine A Marsteller, M.D. received $147.35 in general payments during 2025 across 8 reported records.
ABBVIE INC. accounted for 40.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Myrbetriq by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $59.02 | 40.0% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $36.53 | 24.8% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $20.49 | 13.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $17.02 | 11.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.29 | 9.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $147.35 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $37.64 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $36.53 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.38 | 1 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Biogen, Inc. | $20.49 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $14.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 437 | 103 |
| Levothyroxine Sodium | Levothyroxine Sodium | 423 | 85 |
| Gabapentin | Gabapentin | 371 | 61 |
| Omeprazole | Omeprazole | 364 | 84 |
| Lisinopril | Lisinopril | 298 | 68 |
| Montelukast Sodium | Montelukast Sodium | 289 | 65 |
| Amlodipine Besylate | Amlodipine Besylate | 229 | 53 |
| Metformin Hcl | Metformin Hcl | 200 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 186 | 46 |
| Potassium Chloride | Potassium Chloride | 185 | 37 |
| Ozempic | Semaglutide | 178 | 33 |
| Alprazolam | Alprazolam | 175 | 30 |
| Tramadol Hcl | Tramadol Hcl | 171 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 170 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 168 | 41 |
| Losartan Potassium | Losartan Potassium | 167 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 166 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 164 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 162 | 28 |
| Furosemide | Furosemide | 157 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 154 | 38 |
| Famotidine | Famotidine | 148 | 31 |
| Trazodone Hcl | Trazodone Hcl | 139 | 27 |
| Alendronate Sodium | Alendronate Sodium | 138 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 136 | 29 |
| Buspirone Hcl | Buspirone Hcl | 133 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 131 | 27 |
| Sertraline Hcl | Sertraline Hcl | 131 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 128 | 28 |
| Clonazepam | Clonazepam | 124 | 16 |
| Simvastatin | Simvastatin | 122 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 107 | 20 |
| Azelastine Hcl | Azelastine Hcl | 103 | 48 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 100 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 96 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 92 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 91 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 80 | 20 |
| Meloxicam | Meloxicam | 79 | 21 |
| Pregabalin | Pregabalin | 78 | 11 |
| Allopurinol | Allopurinol | 75 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 72 | 23 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 66 | 15 |
| Diazepam | Diazepam | 66 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 66 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 65 | 17 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 64 | 13 |
| Topiramate | Topiramate | 61 | suppressed |
| Glipizide Er | Glipizide | 59 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 59 | 29 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 59 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 59 | suppressed |
| Bupropion Xl | Bupropion Hcl | 58 | 15 |
| Carvedilol | Carvedilol | 57 | 12 |
| Baclofen | Baclofen | 56 | 14 |
| Nystatin | Nystatin | 55 | 18 |
| Glipizide | Glipizide | 53 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 41 |
| Eliquis | Apixaban | 48 | suppressed |
| Januvia | Sitagliptin Phosphate | 48 | suppressed |
| Mirtazapine | Mirtazapine | 48 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 48 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 47 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | suppressed |
| Movantik | Naloxegol Oxalate | 44 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 44 | suppressed |
| Prednisone | Prednisone | 44 | 25 |
| Ezetimibe | Ezetimibe | 41 | suppressed |
| Linzess | Linaclotide | 41 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 41 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | suppressed |
| Fluconazole | Fluconazole | 40 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 40 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 39 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 39 | suppressed |
| Trulicity | Dulaglutide | 38 | 11 |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Cimetidine | Cimetidine | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Rybelsus | Semaglutide | 34 | suppressed |
| Spironolactone | Spironolactone | 34 | suppressed |
| Acyclovir | Acyclovir | 33 | suppressed |
| Estradiol | Estradiol | 33 | 13 |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Ondansetron Odt | Ondansetron | 33 | 17 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Lorazepam | Lorazepam | 32 | suppressed |
| Valsartan | Valsartan | 32 | suppressed |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 29 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | 17 |
| Ibuprofen | Ibuprofen | 29 | 13 |
| Meclizine Hcl | Meclizine Hcl | 29 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 28 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 28 | 11 |
| Finasteride | Finasteride | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 17 |
| Fenofibrate | Fenofibrate,micronized | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 14 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Jardiance | Empagliflozin | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Belsomra | Suvorexant | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Azathioprine | Azathioprine | 19 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 18 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Ramelteon | Ramelteon | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Austedo | Deutetrabenazine | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | 12 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Drospirenone-Ethinyl Estradiol | Ethinyl Estradiol/Drospirenone | 11 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 11 | suppressed |
| Humira Pen | Adalimumab | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Klayesta | Nystatin | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | 11 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $147.35 · 8 records | ABBVIE INC. | Auvelity, UBRELVY, VRAYLAR, Veozah, ZORYVE, ZURZUVAE | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vraylar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error